USANA Health Sciences (NYSE:USNA) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of USANA Health Sciences (NYSE:USNA) from a buy rating to a hold rating in a research note published on Saturday morning.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Zacks Research cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. Two equities research analysts have rated the stock with a Sell rating, According to data from MarketBeat, USANA Health Sciences currently has an average rating of “Sell”.

USANA Health Sciences Trading Up 3.6%

USANA Health Sciences stock opened at $15.43 on Friday. USANA Health Sciences has a 1 year low of $14.35 and a 1 year high of $32.32. The company has a market cap of $284.84 million, a PE ratio of -12.75, a PEG ratio of 1.70 and a beta of 0.73. The company’s 50-day moving average is $20.41 and its two-hundred day moving average is $19.66.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.50). The business had revenue of $223.27 million for the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%.USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Research analysts forecast that USANA Health Sciences will post 0.76 EPS for the current year.

Insiders Place Their Bets

In other USANA Health Sciences news, Director John Turman Fleming sold 2,450 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $17.93, for a total value of $43,928.50. Following the completion of the transaction, the director directly owned 4,230 shares of the company’s stock, valued at approximately $75,843.90. The trade was a 36.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brent Neidig sold 5,002 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total value of $97,288.90. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 13,869 shares of company stock worth $261,441. Corporate insiders own 0.82% of the company’s stock.

Institutional Trading of USANA Health Sciences

Large investors have recently bought and sold shares of the business. Versant Capital Management Inc lifted its stake in USANA Health Sciences by 1,472.3% in the second quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock valued at $34,000 after buying an additional 1,487 shares in the last quarter. National Bank of Canada FI boosted its holdings in shares of USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after buying an additional 1,201 shares during the period. State of Wyoming bought a new stake in shares of USANA Health Sciences during the first quarter worth $57,000. Tower Research Capital LLC TRC increased its position in shares of USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after acquiring an additional 1,901 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of USANA Health Sciences by 1,354.3% during the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after acquiring an additional 3,589 shares during the period. 54.25% of the stock is owned by institutional investors.

Key Stories Impacting USANA Health Sciences

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti raised its Q3 2026 EPS estimate to $0.11 from $0.09, its Q1 2027 estimate to $0.34 from $0.31, and its Q2 2027 estimate to $0.46 from $0.43. These revisions provide a modest positive signal for USANA’s near-term earnings outlook. MarketBeat USANA analyst estimates
• Neutral Sentiment: USANA recently reported a quarterly loss of $0.07 per share, missing the $0.43 consensus estimate, while revenue of $223.27 million fell short of the $235 million forecast. Management’s fiscal 2026 guidance remains $0.76 EPS, leaving investors focused on whether upcoming results can support the revised outlook.
• Negative Sentiment: Zacks Research downgraded USANA from “Hold” to “Strong Sell,” adding a prominent bearish signal after the company’s earnings miss and prolonged share-price weakness. Zacks Research
• Negative Sentiment: Wall Street Zen also lowered its stock rating, reinforcing the negative analyst sentiment surrounding USANA. Wall Street Zen rating article
• Negative Sentiment: Sidoti’s broader forecast changes were sharply negative: its fiscal 2026 EPS estimate fell to $0.76 from $2.12, fiscal 2027 fell to $1.77 from $2.77, and several quarterly estimates were cut substantially. This suggests the latest upward revisions are limited and do not reverse the firm’s deteriorating earnings expectations.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.